AccuMedical Beijing Inc. (hereinafter “AccuMedical” or “we”) is a commercialized innovative medical device company specializing in the field of neurointervention. Founded in 2017, AccuMedical is headquartered in Beijing with dual R&D centers in China and the United States.
AccuMedical has developed comprehensive businesses including R&D, production, and marketing of neurointerventional devices for the treatment of hemorrhagic and ischemic strokes. Our mission is to offer a whole set of innovative solutions to a global population of cerebrovascular disease patients and physicians.
Lattice approved for the Special Review Process for Innovative Medical Devices (Green Channel) by the National Medical Products Administration (NMPA).
AccuMedical was designated as a "Specialized and Sophisticated SMEs" by the Beijing Municipal Economic and Information Bureau.
AccuMedical obtained certification for the enterprise intellectual property management system and the production of medical devices (license).
Completion of pre-market clinical trial, LIFE (Lattice Intracranial Flow Diverter Evaluation of Clinical Use)
Cosine71/58 Distal Access Catheter approved for marketing by NMPA
Sine approved for marketing by NMPA.
AccuMedical was included in the "Beijing Intellectual Property Pilot Enterprise" by the Beijing Intellectual Property Bureau.
Lattice approved for marketing by NMPA.
Sine 21 Microcatheter approved for marketing by NMPA
Cosine 45 Distal Access Catheter approved for marketing by NMPA
Attractor Aspiration Catheter approved for marketing by NMPA
We are committed to carrying out continuous research and R&D of products and treatments for satisfying the clinical requirements of cerebrovascular diseases. We have established two R&D Centers both in Beijing, China and California, the US, where front technologies of innovative neurointerventional devices have been developed. An international, cross-subject and highly experienced R&D team has been established and a complete R&D system has been formed. In addition, we also have made great breakthroughs and seized the core technologies involving the designing, R&D and production of neurointerventional medical devices, by which a number of self-developed core technologies have been realized. Currently, we have been granted for over 10 patents, including several patents approved by both China and the US, even with some certified international pioneering patented technologies.
Through years of continuous research and investment, AccuMedical has developed refined production technologies, set up global top-class and whole-process production technology system and collected proprietary technological parameters in designing, R&D and production, which contributes to effectively developing and producing highly precise neurointerventional medical devices on a large scale, ensuring the high quality and reliability of products while satisfying global market requirements.
Lattice®, the first flow diverter with mechanical balloon delivery system and Metal Interface Reassembly for Optimizing Restenosis (MIROR), has been approved for marketing by AccuMedical. With high effectiveness and safety, Lattice® is applicable for the maximum indications among all the devices of the same kinds, which not only represents a simplification and innovation of the treatment, but also can significantly improve the prognosis. With superb performances, our commercialized products have been widely applied in clinical practice and are highly recognized by physicians.
AccuMedical has an excellent R&D and management team that is professional, innovative and shares common values. The major managing personnel have rich experience in the medical industry both in the technical and managerial aspects. They have insights and comprehensive understandings of the policies and trends with experiences in designing, production, and marketing and sales, which lays a solid foundation for us to realize commercialization and sustainable operation.
Treat, as our own. With the concept of self-reliance and self-improvement in science and technology, AccuMedical adheres to the corporate value of "treating patients as family". We aim to offer innovative treatment solutions for global patients and physicians, and introduce the medical devices, which are created and made completely in China, to the world.
Through the “Integration of Clinical and Design” and by continuous R&D, AccuMedical keeps developing new innovative patents and promoting core technologies. We offer targeted treatment solutions of cerebrovascular diseases for patients and physicians to lead the innovative development in the field of the neurointerventional treatment.